Funded Biotechnology Startups in Singapore
Biotechnology financing in Singapore shows a wide disclosed-range: the largest disclosed round is RVAC Medicines’ $140M on 2022-04-26, which dwarfs the nex…
Biotechnology financing in Singapore shows a wide disclosed-range: the largest disclosed round is RVAC Medicines’ $140M on 2022-04-26, which dwarfs the next-highest disclosed amounts (Nuevocor at $45M on 2025-05-06 and Mirxes at $40M on 2025-01-13). At the other end, the smallest disclosed amount is $100K, appearing as BioDefense ($100K on 2024-05-14) and Touché ($100K on 2022-03-14), creating a clear spread from seed-to-multi-$10M levels.
The most recent activity clusters tightly in early 2025–Q1 2026: 8 of the 29 rows fall between 2024-12-31 and 2026-03-04, including the 2026-03-31 VolitionRx ($2M) and 2026-03-04 ImmunoScape (undisclosed). Staging and disclosure are mixed, with “Series Unknown” appearing in 7 of 29 entries (e.g., VolitionRx on 2026-03-31; Aevice Health on 2025-01-15; Apeiron Bioenergy on 2023-06-23) and “undisclosed” amounts also appearing in 7 of 29 (e.g., ImmunoScape 2026-03-04; ImpacFat 2025-10-01; Carcell Biopharma 2023-11-13). Dates span 2020-12-17 (TurtleTree Labs) through 2026-03-31 (VolitionRx), and all rows list Singapore (Central Region) as the location.
Most recent rounds
29 shownRelated listings
Frequently asked
What’s the largest disclosed biotech round here, and how much bigger is it than the rest?
RVAC Medicines’ $140M on 2022-04-26 is the largest disclosed amount in the 29-row list, materially higher than the next-largest disclosed rounds: Nuevocor’s $45M (2025-05-06) and Mirxes’ $40M (2025-01-13).
Do recent rounds cluster in a narrow time window, or are they evenly spread?
Activity is back-loaded: 8 of 29 rows fall between 2024-12-31 and 2026-03-04, including VolitionRx on 2026-03-31 ($2M) and ImmunoScape on 2026-03-04 (undisclosed). The overall span runs from 2020-12-17 (TurtleTree Labs) to 2026-03-31 (VolitionRx).
Which disclosure patterns dominate: “Series Unknown” vs “undisclosed” amounts?
“Series Unknown” appears in 7 of 29 entries (e.g., VolitionRx 2026-03-31; Aevice Health 2025-01-15; Apeiron Bioenergy 2023-06-23). Separately, “undisclosed” amounts also appear in 7 of 29 entries (e.g., ImmunoScape 2026-03-04; ImpacFat 2025-10-01; Carcell Biopharma 2023-11-13).
Are there notable stage clusters, or is the list spread across multiple funding stages?
The list is not concentrated in a single stage: it includes Seed (e.g., Auristone $4M on 2024-04-02), Series A (e.g., Automera $16M on 2023-09-27), and higher rounds like Series C (e.g., SCG Cell Therapy $8M on 2023-04-05; Curiox Biosystems $15M on 2022-03-16), alongside multiple “Series Unknown” entries (e.g., Nuevocor’s Series B vs VolitionRx’s Series Unknown).
Are there small-dollar outliers worth flagging for underwriting questions?
Yes: the lowest disclosed amount is $100K, shown twice—BioDefense at $100K on 2024-05-14 and Touché at $100K on 2022-03-14 (Debt Financing). Compared with the $2M–$45M+ disclosed rounds like VolitionRx ($2M, 2026-03-31) and Nuevocor ($45M, 2025-05-06), these $100K rounds stand out as materially smaller disclosed checks.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.